Direct Answer
Amgen Inc.'s SEC filings show revenue of $14.8 billion in fiscal 2007 and $36.8 billion in fiscal 2025, a compound annual growth rate of 5.2%. Its Form 8-K filings report three completed acquisitions in that period (worldwide rights to Otezla (apremilast), from Celgene Corporation in 2019, Five Prime Therapeutics, Inc. in 2021 and Horizon Therapeutics plc in 2023).
Key Milestones
Company-history milestones are listed by year. Events from Amgen Inc.'s SEC filing record are dated by the filing that reports them and link to it.
| Year | Milestone | Source |
|---|---|---|
| 1980 | The company was founded as Applied Molecular Genetics, later adopting the name Amgen. | Company history |
| 1980 | Amgen advanced recombinant-DNA medicines that helped establish biotechnology as a commercial industry. | Company history |
| 1989 | A major anemia therapy received U.S. approval, becoming one of the company's foundational products. | Company history |
| 1990 | Amgen expanded across supportive cancer care, inflammation, bone health, cardiovascular disease, and other areas. | Company history |
| 2019 | Completed acquisition of worldwide rights to Otezla (apremilast), from Celgene Corporation. | Form 8-K filed November 21, 2019 |
| 2021 | Completed acquisition of Five Prime Therapeutics, Inc. | Form 8-K filed April 16, 2021 |
| 2023 | Completed acquisition of Horizon Therapeutics plc. | Form 8-K filed October 6, 2023 |
How Has Amgen Inc.'s Revenue Grown?
The fastest year was fiscal 2024, when revenue grew 18.6%. Revenue fell in three years: fiscal 2009 (-2.4%), fiscal 2017 (-0.6%) and fiscal 2019 (-1.6%); the 10-K for each of those years explains what drove it. Revenue first passed $25 billion in fiscal 2020.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 ended December 31, 2025 | $36.8 billion | 10.0% |
| FY2024 ended December 31, 2024 | $33.4 billion | 18.6% |
| FY2023 ended December 31, 2023 | $28.2 billion | 7.1% |
| FY2022 ended December 31, 2022 | $26.3 billion | 1.3% |
| FY2021 ended December 31, 2021 | $26.0 billion | 2.2% |
| FY2020 ended December 31, 2020 | $25.4 billion | 8.8% |
| FY2019 ended December 31, 2019 | $23.4 billion | -1.6% |
| FY2018 ended December 31, 2018 | $23.7 billion | 3.9% |
| FY2017 ended December 31, 2017 | $22.8 billion | -0.6% |
| FY2016 ended December 31, 2016 | $23.0 billion | 6.1% |
| FY2015 ended December 31, 2015 | $21.7 billion | 8.0% |
| FY2014 ended December 31, 2014 | $20.1 billion | 7.4% |
| FY2013 ended December 31, 2013 | $18.7 billion | 8.2% |
| FY2012 ended December 31, 2012 | $17.3 billion | 10.8% |
| FY2011 ended December 31, 2011 | $15.6 billion | 3.5% |
| FY2010 ended December 31, 2010 | $15.1 billion | 2.8% |
| FY2009 ended December 31, 2009 | $14.6 billion | -2.4% |
| FY2008 ended December 31, 2008 | $15.0 billion | 1.6% |
| FY2007 ended December 31, 2007 | $14.8 billion | n/a |
How Do These Events Affect Amgen Inc.'s Financial History?
Acquisitions and disposals break the comparison from one year to the next. Growth in fiscal 2019, fiscal 2021 and fiscal 2023 and the year after mixes the existing business with what was bought or sold, so the 10-K's discussion of results, which usually separates the two, says more than the headline growth rate in those years.
Each year shows the revenue from the latest 10-K that reported it, so a year a company later restated can differ from the figure it first published, and most companies moved to a new revenue tag after the 2018 change in revenue accounting.
Where This Timeline Comes From
Revenue, stock splits and former names come from Amgen Inc.'s filings with the SEC, read from EDGAR's XBRL company facts and submissions data on October 5, 2026. Acquisitions and disposals are those reported as completed under Item 2.01 of a Form 8-K in the filings EDGAR lists for the company, each checked against the filing itself. Milestones marked "Company history" summarize widely reported events and are dated by year only. This page is educational and describes history; it is not a forecast or a recommendation.
Frequently Asked Questions
How much has Amgen Inc.'s revenue grown?
From $14.8 billion in fiscal 2007 to $36.8 billion in fiscal 2025, a compound annual growth rate of 5.2%, according to the revenue Amgen Inc. reported in its Form 10-K filings.
What major acquisitions has Amgen Inc. completed?
Amgen Inc.'s Form 8-K filings report completing the acquisition of worldwide rights to Otezla (apremilast), from Celgene Corporation (November 2019), Five Prime Therapeutics, Inc. (April 2021) and Horizon Therapeutics plc (October 2023). Each is linked to its filing in the milestone table.
Has Amgen Inc.'s revenue ever declined?
Yes, in fiscal 2009 (-2.4%), fiscal 2017 (-0.6%) and fiscal 2019 (-1.6%), based on the revenue reported in its 10-K filings.